Asset Identification:
- Name and description of the clinical asset (e.g., drug candidate, biologic, medical device).
- Therapeutic area and mechanism of action (MOA).
- Current development stage (e.g., pre-clinical, Phase 1, Phase 2, registration, or already marketed).
- Relevant intellectual property status, including patents and copyrights.
- Regulatory status (e.g., existing IND application, previous communications with the FDA or other regulatory bodies).
Clinical and Scientific Data:
- Summary of all conducted pre-clinical and clinical studies, including protocols, results, and safety data.
- Information on the unmet medical need the asset addresses and its differentiation from existing standard-of-care treatments.
- Documentation of clinical proof-of-concept (POC), including Phase 2 data if available, which is a key value inflection point.
Commercial and Market Potential:
- Target patient population and estimated market size.
- Competitive landscape analysis (efficacy, safety, dosing, cost).
- Proposed target market(s) or geographic territory for the license.
Logistics and Manufacturing:
- Manufacturing considerations (e.g., special handling, controlled substances).
- Stability data on the medicinal product and supply chain details.
- Proposed Deal Terms:
- Requested financial structure (e.g., upfront payment, milestone payments, royalties).
- Proposed license duration and other key terms and conditions.